#USA #New Orleans #Immusoft #B Cells #MPS I

Immusoft to Present at ASGCT 2025

Immusoft, a California-based cell therapy company, is preparing to unveil compelling clinical trial results of its innovative engineered B cells at the 28th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT) 2025, scheduled to take place from May 13-17 in New Orleans, Louisiana. The data being presented has significant implications for patients with Mucopolysaccharidosis type I (MPS I), underlining the advancements in therapeutic protein delivery through cellular engineering.

Presentation Overview

Dr. Paul J. Orchard, a prominent figure in pediatric blood and marrow transplantation, will be the presenter of the findings at a key session focused on Gene Therapy Clinical Trials. The oral abstract title is "Autologous Human Peripheral Blood B Cells Genetically Engineered to Express Human Iduronidase: Results from a First-in-Human Clinical Trial in Subjects with Mucopolysaccharidosis Type I." This presentation is crucial as it showcases the effectiveness of Immusoft’s lead investigational candidate, ISP-001, designed specifically for MPS I.

Date and Location

Dr. Orchard's presentation will occur on Wednesday, May 14th, from 1:30 PM to 3:15 PM CT at the New Orleans Theater B, rendering it a must-attend for those interested in the future of gene therapy and treatment for rare diseases.

Breakthrough Findings

Immusoft's clinical trial represents a pioneering step as it involves patients receiving their autologous B cells without the burdens of a preconditioning regimen—commonly necessary for gene-modified stem cells—and without the need for immunosuppression that is usually required for systemic virus-delivered gene therapies. The implications of such an approach are profound, given the potential for reduced side effects and the enhanced safety profile of the treatment.

This trial highlights the promise of engineered B cells not just for MPS I but also opens avenues for addressing other diseases where therapeutic proteins can play a critical role. The natural capacity of B cells to engraft within the bone marrow and produce high levels of therapeutic proteins presents a transformative approach for various therapeutic indications.

Addressing Unmet Needs

MPS I, a rare lysosomal storage disorder, currently has limited treatment options primarily revolving around enzyme replacement therapies (ERT) or hematopoietic stem cell transplants (HSCT). The demand for new therapies that can offer better efficacy and convenience is urgent. Immusoft's focus on using reprogrammed B cells as durable biofactories could be the answer many patients have been waiting for. As the company continues to explore the possibilities of B cells, the implications for treating other rare diseases could be groundbreaking.

About Immusoft

Founded in Seattle, Washington, Immusoft is at the forefront of cell therapy innovation. Their unique platform known as Immune System Programming (ISP™) enables the modification of patients' B cells, instructing them to produce protein therapeutics. This transformative approach positions B cells as miniature drug factories with the potential for long-term therapeutic effects, keeping patients’ health needs at the forefront.

To learn more about Immusoft and its revolutionary developments in cell therapies, please visit www.immusoft.com.

Looking Ahead

The upcoming presentation at ASGCT 2025 signifies a crucial milestone not only for Immusoft but also for the entire field of gene therapy and its capacity to change lives. As the landscape of treatment options for rare diseases evolves, the promise of engineered B cells offers new hope for patients and families impacted by conditions like MPS I.